1. Home
  2. DUO vs MTVA Comparison

DUO vs MTVA Comparison

Compare DUO & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DUO
  • MTVA
  • Stock Information
  • Founded
  • DUO 2011
  • MTVA 2014
  • Country
  • DUO China
  • MTVA United States
  • Employees
  • DUO N/A
  • MTVA N/A
  • Industry
  • DUO Real Estate
  • MTVA
  • Sector
  • DUO Finance
  • MTVA
  • Exchange
  • DUO Nasdaq
  • MTVA NYSE
  • Market Cap
  • DUO 17.1M
  • MTVA 18.9M
  • IPO Year
  • DUO 2019
  • MTVA N/A
  • Fundamental
  • Price
  • DUO $0.61
  • MTVA $1.95
  • Analyst Decision
  • DUO
  • MTVA Strong Buy
  • Analyst Count
  • DUO 0
  • MTVA 1
  • Target Price
  • DUO N/A
  • MTVA $12.00
  • AVG Volume (30 Days)
  • DUO 2.0M
  • MTVA 337.7K
  • Earning Date
  • DUO 08-30-2024
  • MTVA 11-07-2024
  • Dividend Yield
  • DUO N/A
  • MTVA N/A
  • EPS Growth
  • DUO N/A
  • MTVA N/A
  • EPS
  • DUO N/A
  • MTVA N/A
  • Revenue
  • DUO $37,352,654.00
  • MTVA N/A
  • Revenue This Year
  • DUO N/A
  • MTVA N/A
  • Revenue Next Year
  • DUO N/A
  • MTVA N/A
  • P/E Ratio
  • DUO N/A
  • MTVA N/A
  • Revenue Growth
  • DUO 6.61
  • MTVA N/A
  • 52 Week Low
  • DUO $0.32
  • MTVA $1.51
  • 52 Week High
  • DUO $4.67
  • MTVA $6.75
  • Technical
  • Relative Strength Index (RSI)
  • DUO 46.04
  • MTVA N/A
  • Support Level
  • DUO $0.53
  • MTVA N/A
  • Resistance Level
  • DUO $0.62
  • MTVA N/A
  • Average True Range (ATR)
  • DUO 0.05
  • MTVA 0.00
  • MACD
  • DUO 0.00
  • MTVA 0.00
  • Stochastic Oscillator
  • DUO 43.82
  • MTVA 0.00

About DUO Fangdd Network Group Ltd.

Fangdd Network Group Ltd is an investment holding company. Through its subsidiaries, It is engaged in the provision of real estate information services through its online platform which also offers integrated marketing services for individual customers, real estate developers, and agents in China. Its SaaS-based solutions help real estate agents to connect with essential business resources, including customers, property listings, capital, and transaction data. The company generates the majority of its revenue from Base commission from transactions in China.

About MTVA METAVIA INC

MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.

Share on Social Networks: